Current trends and future perspectives for enhanced drug delivery to central nervous system in treatment of stroke

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Kapral MK, Laupacis A, Phillips SJ et al. Stroke care delivery in institutions participating in the Registry of the Canadian Stroke Network. Stroke 35(7), 1756–1762 (2004).
  MedlineGoogle Scholar
• 2. Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years: a doubling of treatment rates over the course of 5 years. Stroke 42(7), 1952–1955 (2011).
  Medline CASGoogle Scholar
• 3. Stolz E, Hamann GF, Kaps M, Misselwitz B. Regional differences in acute stroke admission and thrombolysis rates in the German federal state of Hesse. Dtsch. Arztebl. Int. 108(36), 607–611 (2011).
  MedlineGoogle Scholar
• 4. Stecksén A, Asplund K, Appelros P et al. Thrombolytic therapy rates and stroke severity: an analysis of data from the Swedish stroke register (Riks-Stroke) 2007–2010: an analysis of data from the Swedish stroke register (Riks-stroke) 2007–2010. Stroke 43(2), 536–538 (2012).
  MedlineGoogle Scholar
• 5. Rabinstein A. Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke. Year B. Neurol. Neurosurg. 2009, 9–12 (2009).
  Google Scholar
• 6. Lyerly MJ, Albright KC, Boehme AK et al. The potential impact of maintaining a 3-hour IV thrombolysis window: how many more patients can we safely treat? J. Neurol. Disord. Stroke. 1(2), 1015 (2013).
  MedlineGoogle Scholar
• 7. Nambiar V, Sudevan R, Arumugam Premalatha P, Babu S, Vasudevan A. Prediction of outcomes in stroke patients from radiological findings – A hospital-based retrospective cohort study from a comprehensive stroke care center in Kerala, India. Amrita J Med. 16(3), 105 (2020).
  Google Scholar
• 8. Campbell BCV, Mitchell PJ, Kleinig TJ et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N. Engl. J. Med. 372(11), 1009–1018 (2015).
  Medline CASGoogle Scholar
• 9. Goyal M, Demchuk AM, Menon BK et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N. Engl. J. Med. 372(11), 1019–1030 (2015).
  Medline CASGoogle Scholar
• 10. Gurol ME. Nonpharmacological management of atrial fibrillation in patients at high intracranial hemorrhage risk. Stroke 49(1), 247–254 (2018).
  MedlineGoogle Scholar
• 11. Adams HP Jr, Bendixen BH, Kappelle LJ et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24(1), 35–41 (1993).
  MedlineGoogle Scholar
• 12. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol. 12(5), 483–497 (2013).
  MedlineGoogle Scholar
• 13. Tsai H-H, Kim JS, Jouvent E, Gurol ME. Updates on prevention of hemorrhagic and lacunar strokes. J. Stroke. 20(2), 167–179 (2018).
  MedlineGoogle Scholar
• 14. Topcuoglu MA, Liu L, Kim D-E, Gurol ME. Updates on prevention of cardioembolic strokes. J. Stroke. 20(2), 180–196 (2018).
  MedlineGoogle Scholar
• 15. Steffel J, Verhamme P, Potpara TS et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur. Heart J. 39(16), 1330–1393 (2018).
  Medline CASGoogle Scholar
• 16. Hsu JC, Maddox TM, Kennedy KF et al. Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: Insights from the NCDR PINNACLE registry. JAMA Cardiol. 1(1), 55–62 (2016).
  MedlineGoogle Scholar
• 17. Tsivgoulis G, Safouris A, Kim D-E, Alexandrov AV. Recent advances in primary and secondary prevention of atherosclerotic stroke. J. Stroke. 20(3), 417 (2018).
  MedlineGoogle Scholar
• 18. Radomska A, Leszczyszyn J, Radomski MW. The nanopharmacology and nanotoxicology of nanomaterials: new opportunities and challenges. Adv. Clin. Exp. Med. 25(1), 151–162 (2016).
  MedlineGoogle Scholar
• 19. Rhee J-W, Wu JC. Advances in nanotechnology for the management of coronary artery disease. Trends Cardiovasc. Med. 23(2), 39–45 (2013).
  Medline CASGoogle Scholar
• 20. Janko C, Dürr S, Munoz LE et al. Magnetic drug targeting reduces the chemotherapeutic burden on circulating leukocytes. Int. J. Mol. Sci. 14(4), 7341–7355 (2013).
  Medline CASGoogle Scholar
• 21. Bietenbeck M, Florian A, Faber C, Sechtem U, Yilmaz A. Remote magnetic targeting of iron oxide nanoparticles for cardiovascular diagnosis and therapeutic drug delivery: where are we now? Int. J. Nanomedicine. 11, 3191–3203 (2016).
  Medline CASGoogle Scholar
• 22. Das A, Mukherjee P, Singla SK et al. Fabrication and characterization of an inorganic gold and silica nanoparticle mediated drug delivery system for nitric oxide. Nanotechnology. 21(30), 305102 (2010).
  MedlineGoogle Scholar
• 23. Dieterlen M-T, John K, Reichenspurner H, Mohr FW, Barten MJ. Dendritic cells and their role in cardiovascular diseases: a view on human studies. J. Immunol. Res. 2016, 5946807 (2016).
  MedlineGoogle Scholar
• 24. Sharma M, Sharma R, Jain DK. Nanotechnology based approaches for enhancing oral bioavailability of poorly water soluble antihypertensive drugs. Scientifica (Cairo). 2016, 8525679 (2016).
  MedlineGoogle Scholar
• 25. Kumar P, Agnihotri S. Synthesis of dox drug conjugation and citric acid stabilized superparamagnetic iron-oxide nanoparticles for drug delivery. Biochem. Physiol. 1(5), (2016).
  Google Scholar
• 26. Lassenberger A, Scheberl A, Stadlbauer A, Stiglbauer A, Helbich T, Reimhult E. Individually stabilized, superparamagnetic nanoparticles with controlled shell and size leading to exceptional stealth properties and high relaxivities. ACS Appl. Mater. Interfaces. 9(4), 3343–3353 (2017).
  Medline CASGoogle Scholar
• 27. Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. Classification of stroke subtypes. Cerebrovasc. Dis. 27(5), 493–501 (2009).
  Medline CASGoogle Scholar
• 28. Goldstein LB, Adams R, Alberts MJ et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 37(6), 1583–1633 (2006).
  MedlineGoogle Scholar
• 29. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(Suppl. 3), S483–S512 (2004).
  Google Scholar
• 30. European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc. Dis. 25(5), 457–507 (2008).
  MedlineGoogle Scholar
• 31. Pedelty L, Gorelick PB. Update on the management of hypertension to prevent stroke. Curr. Treat. Options Neurol. 8(6), 486–495 (2006).
  MedlineGoogle Scholar
• 32. King A, Markus HS. Doppler embolic signals in cerebrovascular disease and prediction of stroke risk: a systematic review and meta-analysis: a systematic review and meta-analysis. Stroke 40(12), 3711–3717 (2009).
  MedlineGoogle Scholar
• 33. Wohlschlaeger J, Wimmer MLJ, Nägler DK, Haberl R, Weis S. Identification of Chlamydia pneumoniae in intracranial and extracranial arteries in patients with stroke and in controls: combined immunohistochemical and polymerase chain reaction analyses. Hum. Pathol. 36(4), 395–402 (2005).
  MedlineGoogle Scholar
• 34. Gao T, Zhang Z, Yu W, Zhang Z, Wang Y. Atherosclerotic carotid vulnerable plaque and subsequent stroke: a high-resolution MRI study. Cerebrovasc. Dis. 27(4), 345–352 (2009).
  MedlineGoogle Scholar
• 35. Hamdy S, Fathy M, Elnasser AA et al. Vasomotor reactivity in patients with cerebral small vessel disease vs. internal border zone infarction and its correlation with disease outcome. Egypt. J. Neurol. Psychiatr. Neurosurg. 58(1), (2022).
  Google Scholar
• 36. Lozano JD, Abulafia DP, Danton GH, Watson BD, Dietrich WD. Characterization of a thromboembolic photochemical model of repeated stroke in mice. J. Neurosci. Methods 162(1–2), 244–254 (2007).
  Medline CASGoogle Scholar
• 37. Kim BJ, Menon BK, Kim JY et al. Endovascular Treatment after stroke due to large vessel occlusion for patients presenting very late from time last known well. JAMA Neurol. 78(1), 21 (2020).
  MedlineGoogle Scholar
• 38. Pham M, Bendszus M. Facing time in ischemic stroke: an alternative hypothesis for collateral failure. Clin. Neuroradiol. 26(2), 141–151 (2016).
  Medline CASGoogle Scholar
• 39. Millikan C, Futrell N. The fallacy of the lacune hypothesis. Stroke 21(9), 1251–1257 (1990).
  Medline CASGoogle Scholar
• 40. Sheth SA, Lopez-Rivera V, Lee S et al. 14th International Symposium on Thrombolysis, Thrombectomy and Acute Stroke Therapy: proceedings and summary of discussions. Int. J. Stroke. 14(4), 439–441 (2019).
  MedlineGoogle Scholar
• 41. Muir KW, Roberts M. Thrombolytic therapy for stroke: a review with particular reference to elderly patients. Drugs Aging 16(1), 41–54 (2000).
  Medline CASGoogle Scholar
• 42. Demel SL, Stanton R, Aziz YN, Adeoye O, Khatri P. Reflection on the past, present, and future of thrombolytic therapy for acute ischemic stroke. Neurology 97(2 Suppl. 20), S170–S177 (2021).
  MedlineGoogle Scholar
• 43. Chen H, Shen J, Zhao H. Ischemic postconditioning for stroke treatment: current experimental advances and future directions. Cond. Med. 3(2), 104–115 (2020).
  MedlineGoogle Scholar
• 44. Debette S, Leys D. Cervical-artery dissections: predisposing factors, diagnosis, and outcome. Lancet Neurol. 8(7), 668–678 (2009).
  MedlineGoogle Scholar
• 45. Brandt T, Orberk E, Weber R et al. Pathogenesis of cervical artery dissections: association with connective tissue abnormalities. Neurology 57(1), 24–30 (2001).
  Medline CASGoogle Scholar
• 46. Dziewas R, Konrad C, Dräger B et al. Cervical artery dissection–clinical features, risk factors, therapy and outcome in 126 patients. J. Neurol. 250(10), 1179–1184 (2003).
  MedlineGoogle Scholar
• 47. Baumgartner RW, Arnold M, Baumgartner I et al. Carotid dissection with and without ischemic events: local symptoms and cerebral artery findings. Neurology 57(5), 827–832 (2001).
  Medline CASGoogle Scholar
• 48. Dittrich R, Heidbreder A, Rohsbach D et al. Connective tissue and vascular phenotype in patients with cervical artery dissection. Neurology 68(24), 2120–2124 (2007).
  Medline CASGoogle Scholar
• 49. Touzé E, Gauvrit J-Y, Moulin T et al. Risk of stroke and recurrent dissection after a cervical artery dissection: a multicenter study: a multicenter study. Neurology 61(10), 1347–1351 (2003).
  Medline CASGoogle Scholar
• 50. Touzé E, Randoux B, Méary E, Arquizan C, Meder JF, Mas JL. Aneurysmal forms of cervical artery dissection: associated factors and outcome. Stroke 32(2), 418–423 (2001).
  Medline CASGoogle Scholar
• 51. Griffiths MJ, Winship AL, Stringer JM et al. Prolonged atrazine exposure beginning in utero and adult uterine morphology in mice. J. Dev. Orig. Health Dis. 13(1), 39–48 (2022).
  Medline CASGoogle Scholar
• 52. Sánchez-Soriano C, Pearson ER, Reynolds RM. The role of genetics in fetal programming of adult cardiometabolic disease. J. Dev. Orig. Health Dis. 13(3), 292–299 (2022).
  Medline CASGoogle Scholar
• 53. Barker D. Infant mortality, childhood nutrition, and ischaemic heart disease in England and wales. Lancet 327(8489), 1077–1081 (1986).
  Google Scholar
• 54. Maurizi CP. Short note: the fetal origins hypothesis: linking pineal gland hypoplasia with coronary heart disease and stroke. Med. Hypotheses 50(4), 357–358 (1998).
  Medline CASGoogle Scholar
• 55. NEJM Journal Watch: summaries of and commentary on original medical and scientific articles from key medical journals. Jwatch.org. Available from: www.jwatch.org/fw201003120000001/2010/03/12/hypothesis-links-blood-pressure-variability (Accessed 20 March 2023).
  Google Scholar
• 56. Rothwell PM, Howard SC, Dolan E et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 9(5), 469–480 (2010).
  Medline CASGoogle Scholar
• 57. Berliocchi L, Bano D, Nicotera P. Ca2+ signals and death programmes in neurons. Philos. Trans. R. Soc. Lond. B Biol. Sci. 360(1464), 2255–2258 (2005).
  Medline CASGoogle Scholar
• 58. Hazell AS. Excitotoxic mechanisms in stroke: an update of concepts and treatment strategies. Neurochem. Int. 50(7–8), 941–953 (2007).
  Medline CASGoogle Scholar
• 59. Towfighi A, Ovbiagele B, El Husseini N et al. Poststroke depression: a scientific statement for healthcare professionals from the American Heart Association/American stroke association. Stroke 48(2), e30–e43 (2017).
  MedlineGoogle Scholar
• 60. Kotan Z, Sarandöl E, Kırhan E, Ozkaya G, Kırlı S. Serum brain-derived neurotrophic factor, vascular endothelial growth factor and leptin levels in patients with a diagnosis of severe major depressive disorder with melancholic features. Ther. Adv. Psychopharmacol. 2(2), 65–74 (2012).
  Medline CASGoogle Scholar
• 61. Seshadri S, Beiser A, Pikula A et al. Parental occurrence of stroke and risk of stroke in their children: the Framingham study: The Framingham study. Circulation 121(11), 1304–1312 (2010).
  MedlineGoogle Scholar
• 62. Ushkalova EA, Gushchina YS, Ushkalova EA, Guschina YS. The impact of early intensive glucose control for prophylaxis of complications of type 2 diabetes mellitus (results of UKPDS study and 10-year follow-up study). Obes. Metab. 6(2), 12–18 (2009).
  Google Scholar
• 63. Matarin M, Brown WM, Singleton A, Hardy JA, Meschia JF. ISGS investigators. Whole genome analyses suggest ischemic stroke and heart disease share an association with polymorphisms on chromosome 9p21. Stroke 39(5), 1586–1589 (2008).
  Medline CASGoogle Scholar
• 64. Pulit SL, McArdle PF, Wong Q et al. Loci associated with ischaemic stroke and its subtypes (SiGN): a genome-wide association study. Lancet Neurol. 15(2), 174–184 (2016).
  MedlineGoogle Scholar
• 65. Kubinová S, Syková E. Nanotechnology for treatment of stroke and spinal cord injury. Nanomedicine (Lond.). 5(1), 99–108 (2010).
  Medline CASGoogle Scholar
• 66. Uthaman S, Lee SJ, Cherukula K, Cho C-S, Park I-K. Polysaccharide-coated magnetic nanoparticles for imaging and gene therapy. Biomed Res. Int. 2015, 959175 (2015).
  MedlineGoogle Scholar
• 67. Mu K, Zhang S, Ai T et al. Monoclonal antibody-conjugated superparamagnetic iron oxide nanoparticles for imaging of epidermal growth factor receptor-targeted cells and gliomas. Mol. Imaging. 14(5), 7290201500002 (2015).
  Google Scholar
• 68. Shevtsov MA, Nikolaev BP, Yakovleva LY et al. Superparamagnetic iron oxide nanoparticles conjugated with epidermal growth factor (SPION-EGF) for targeting brain tumors. Int. J. Nanomedicine. 9, 273–287 (2014).
  MedlineGoogle Scholar
• 69. Pehlivan SB. Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases. Pharm. Res. 30(10), 2499–2511 (2013).
  MedlineGoogle Scholar
• 70. Guerra M, Blázquez JL, Rodríguez EM. Blood–brain barrier and foetal-onset hydrocephalus, with a view on potential novel treatments beyond managing CSF flow. Fluids Barriers CNS. 14(1), (2017).
  Google Scholar
• 71. Komarova YA, Kruse K, Mehta D, Malik AB. Protein interactions at endothelial junctions and signaling mechanisms regulating endothelial permeability. Circ. Res. 120(1), 179–206 (2017).
  Medline CASGoogle Scholar
• 72. Lécuyer M-A, Saint-Laurent O, Bourbonnière L et al. Dual role of ALCAM in neuroinflammation and blood-brain barrier homeostasis. Proc. Natl Acad. Sci. U. S. A. 114(4), E524–E533 (2017).
  Medline CASGoogle Scholar
• 73. Castro Dias M, Mapunda JA, Vladymyrov M, Engelhardt B. Structure and junctional complexes of endothelial, epithelial and glial brain barriers. Int. J. Mol. Sci. 20(21), 5372 (2019).
  MedlineGoogle Scholar
• 74. Garg Y, Kapoor DN, Sharma AK, Bhatia A. Drug delivery systems and strategies to overcome the barriers of brain. Curr. Pharm. Des. 28(8), 619–641 (2022).
  MedlineGoogle Scholar
• 75. Goyal D, Shuaib S, Mann S, Goyal B. Rationally designed peptides and peptidomimetics as inhibitors of amyloid-β (Aβ) aggregation: potential therapeutics of Alzheimer's disease. ACS Comb. Sci. 19(2), 55–80 (2017).
  Medline CASGoogle Scholar
• 76. Banks WA. Characteristics of compounds that cross the blood-brain barrier. BMC Neurol. 9(Suppl. 1), S3 (2009).
  MedlineGoogle Scholar
• 77. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 16(1), 1–13 (2004).
  Medline CASGoogle Scholar
• 78. Mäger I, Meyer AH, Li J et al. Targeting blood-brain-barrier transcytosis - perspectives for drug delivery. Neuropharmacology 120, 4–7 (2017).
  Medline CASGoogle Scholar
• 79. Dong X. Current strategies for brain drug delivery. Theranostics. 8(6), 1481–1493 (2018).
  Medline CASGoogle Scholar
• 80. Tosi G, Bortot B, Ruozi B et al. Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier. Curr. Med. Chem. 20(17), 2212–2225 (2013).
  Medline CASGoogle Scholar
• 81. Sanchez-Covarrubias L, Slosky LM, Thompson BJ, Davis TP, Ronaldson PT. Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? Curr. Pharm. Des. 20(10), 1422–1449 (2014).
  Medline CASGoogle Scholar
• 82. Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J. Inherit. Metab. Dis. 36(3), 437–449 (2013).
  Medline CASGoogle Scholar
• 83. Begley DJ, Pontikis CC, Scarpa M. Lysosomal storage diseases and the blood-brain barrier. Curr. Pharm. Des. 14(16), 1566–1580 (2008).
  Medline CASGoogle Scholar
• 84. Mahringer A, Fricker G. ABC transporters at the blood-brain barrier. Expert Opin. Drug Metab. Toxicol. 12(5), 499–508 (2016).
  Medline CASGoogle Scholar
• 85. Rajendran R, Menon KN, Nair SC. Nanotechnology approaches for enhanced CNS drug delivery in the management of schizophrenia. Adv. Pharm. Bull. 12(3), 490–508 (2022). •• This review article, author addresses the main challenges faced in CNS drug delivery and the significance of current therapeutic strategies and nanotherapeutic approaches for a better understanding and enhanced drug delivery approaches to the brain. Author addresses the significant challenges faced in the therapy of CNS disorders and role of fluid biomarkers in the early detection of disease. The merits and demerits of various nanotherapeutic approaches adopted for enhanced CNS drug delivery is also mentioned in detail.
  Medline CASGoogle Scholar
• 86. Arundhasree, Rajalakshmi, Aiswarya, Kumar AR, Kumar SS, Nair SC. Ufasomes: unsaturated fatty acid based vesicular drug delivery system. Int. J. Appl. Pharm. 13(2), 76–83 (2021). • Authors explain that vesicular drug delivery research has rocketed about the evolution of attentive, patient-compliant and cost-effective formulations, devices and systems that can permeate the barriers of the physiological system and as well, as maintain exclusive tissue drug concentration. According to the author, vesicular drug delivery systems are currently highly useful in the field of pharmaceutics, and they tend to have a prominent role in the domain of pharmaceutical dosage forms in addition to the conventional drug delivery system.
  CASGoogle Scholar
• 87. Jose M, Lakshmi A, Nair C. Discosomes: a futuristic upheaval in vesicular drug delivery. International Journal of Applied Pharmaceutics. 13(6), 41–46 (2021). • Authors explain that vesicular drug delivery research has rocketed about the evolution of attentive, patient-compliant and cost-effective formulations, devices and systems that can permeate the barriers of the physiological system and as well, as maintain exclusive tissue drug concentration. According to the author, vesicular drug delivery systems are currently highly useful in the field of pharmaceutics, and they tend to have a prominent role in the domain of pharmaceutical dosage forms in addition to the conventional drug delivery system.
  CASGoogle Scholar
• 88. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2(1), 3–14 (2005).
  MedlineGoogle Scholar
• 89. Sorrentino NC, Fraldi A. Brain targeting in MPS-IIIA. Pediatr. Endocrinol. Rev. 13(Suppl. 1), 630–638 (2016).
  MedlineGoogle Scholar
• 90. Lu C-T, Zhao Y-Z, Wong HL, Cai J, Peng L, Tian X-Q. Current approaches to enhance CNS delivery of drugs across the brain barriers. Int. J. Nanomedicine. 9, 2241–2257 (2014).
  MedlineGoogle Scholar
• 91. Mikitsh JL, Chacko A-M. Pathways for small molecule delivery to the central nervous system across the blood-brain barrier. Perspect. Medicin. Chem. 6, 11–24 (2014).
  MedlineGoogle Scholar
• 92. Pardridge WM. Brain drug targeting and gene technologies. Jpn J. Pharmacol. 87(2), 97–103 (2001).
  Medline CASGoogle Scholar
• 93. Mathison S, Nagilla R, Kompella UB. Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J. Drug Target. 5(6), 415–441 (1998).
  Medline CASGoogle Scholar
• 94. Belur LR, Temme A, Podetz-Pedersen KM et al. Intranasal adeno-associated virus mediated gene delivery and expression of human iduronidase in the central nervous system: a noninvasive and effective approach for prevention of neurologic disease in mucopolysaccharidosis type I. Hum. Gene Ther. 28(7), 576–587 (2017).
  Medline CASGoogle Scholar
• 95. Falcone GJ, Malik R, Dichgans M, Rosand J. Current concepts and clinical applications of stroke genetics. Lancet Neurol. 13(4), 405–418 (2014).
  MedlineGoogle Scholar
• 96. Glushakova OY, Glushakov AV, Miller ER, Valadka AB, Hayes RL. Biomarkers for acute diagnosis and management of stroke in neurointensive care units. Brain Circ. 2(1), 28–47 (2016).
  MedlineGoogle Scholar
• 97. Baudier J, Glasser N, Gerard D. Ions binding to S100 proteins. I. Calcium- and zinc-binding properties of bovine brain S100 alpha alpha, S100a (alpha beta), and S100b (beta beta) protein: zn2+ regulates Ca2+ binding on S100b protein. J. Biol. Chem. 261(18), 8192–8203 (1986).
  Medline CASGoogle Scholar
• 98. Deloulme JC, Raponi E, Gentil BJ et al. Nuclear expression of S100B in oligodendrocyte progenitor cells correlates with differentiation toward the oligodendroglial lineage and modulates oligodendrocytes maturation. Mol. Cell. Neurosci. 27(4), 453–465 (2004).
  Medline CASGoogle Scholar
• 99. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell Biol. 33(7), 637–668 (2001).
  Medline CASGoogle Scholar
• 100. Berger RP, Beers SR, Richichi R, Wiesman D, Adelson PD. Serum biomarker concentrations and outcome after pediatric traumatic brain injury. J. Neurotrauma 24(12), 1793–1801 (2007).
  MedlineGoogle Scholar
• 101. Eng LF. Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes. J. Neuroimmunol. 8, 203–214 (1985).
  Medline CASGoogle Scholar
• 102. Schiff L, Hadker N, Weiser S, Rausch C. A literature review of the feasibility of glial fibrillary acidic protein as a biomarker for stroke and traumatic brain injury. Mol. Diagn. Ther. 16(2), 79–92 (2012).
  Medline CASGoogle Scholar
• 103. Lee JY, Lee CY, Kim HR, Lee C-H, Kim HW, Kim JH. A role of serum-based neuronal and glial markers as potential predictors for distinguishing severity and related outcomes in traumatic brain injury. J. Korean Neurosurg. Soc. 58(2), 93–100 (2015).
  Medline CASGoogle Scholar
• 104. Liu MC, Akinyi L, Scharf D et al. Ubiquitin C-terminal hydrolase-L1 as a biomarker for ischemic and traumatic brain injury in rats. Eur. J. Neurosci. 31(4), 722–732 (2010).
  MedlineGoogle Scholar
• 105. Posti JP, Takala RSK, Runtti H et al. The levels of glial fibrillary acidic protein and ubiquitin C-terminal hydrolase-L1 during the first week after a traumatic brain injury: correlations with clinical and imaging findings. Neurosurgery 79(3), 456–464 (2016).
  MedlineGoogle Scholar
• 106. Papa L, Akinyi L, Liu MC et al. Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit. Care Med. 38(1), 138–144 (2010).
  Medline CASGoogle Scholar
• 107. Cunningham RT, Young IS, Winder J et al. Serum neurone specific enolase (NSE) levels as an indicator of neuronal damage in patients with cerebral infarction. Eur. J. Clin. Invest. 21(5), 497–500 (1991).
  Medline CASGoogle Scholar
• 108. Singh HV, Pandey A, Shrivastava AK, Raizada A, Singh SK, Singh N. Prognostic value of neuron specific enolase and IL-10 in ischemic stroke and its correlation with degree of neurological deficit. Clin. Chim. Acta 419, 136–138 (2013).
  Medline CASGoogle Scholar
• 109. Zhang Z, Larner SF, Liu MC, Zheng W, Hayes RL, Wang KKW. Multiple alphaII-spectrin breakdown products distinguish calpain and caspase dominated necrotic and apoptotic cell death pathways. Apoptosis. 14(11), 1289–1298 (2009).
  Medline CASGoogle Scholar
• 110. Ren C, Zoltewicz S, Guingab-Cagmat J et al. Different expression of ubiquitin C-terminal hydrolase-L1 and αII-spectrin in ischemic and hemorrhagic stroke: potential biomarkers in diagnosis. Brain Res. 1540, 84–91 (2013).
  Medline CASGoogle Scholar
• 111. Cohen SR, Brooks BR, Herndon RM, McKhann GM. A diagnostic index of active demyelination: myelin basic protein in cerebrospinal fluid. Ann. Neurol. 8(1), 25–31 (1980).
  Medline CASGoogle Scholar
• 112. Aurell A, Rosengren LE, Karlsson B, Olsson JE, Zbornikova V, Haglid KG. Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction. Stroke 22(10), 1254–1258 (1991).
  Medline CASGoogle Scholar
• 113. Wang Y, Zhao Z, Montagne A, Griffin JH, Zlokovic B. Abstract WP90: activate protein C analog protects ischemic injury of subcortical white matter in mice. Stroke 49(Suppl. 1), (2018).
  Google Scholar
• 114. Zierath D, Kunze A, Fecteau L, Becker K. Promiscuity of autoimmune responses to MBP after stroke. J. Neuroimmunol. 285, 101–105 (2015).
  Medline CASGoogle Scholar
• 115. Frappier T, Stetzkowski-Marden F, Pradel LA. Interaction domains of neurofilament light chain and brain spectrin. Biochem. J. 275(2), 521–527 (1991).
  Medline CASGoogle Scholar
• 116. Van Geel WJA, Rosengren LE, Verbeek MM. An enzyme immunoassay to quantify neurofilament light chain in cerebrospinal fluid. J. Immunol. Methods 296(1–2), 179–185 (2005).
  Medline CASGoogle Scholar
• 117. Hyeon C, Dima RI, Thirumalai D. Size, shape, and flexibility of RNA structures. J. Chem. Phys. 125(19), 194905 (2006).
  MedlineGoogle Scholar
• 118. Rana TM. Illuminating the silence: understanding the structure and function of small RNAs. Nat. Rev. Mol. Cell Biol. 8(1), 23–36 (2007).
  Medline CASGoogle Scholar
• 119. Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol. Rev. 84(2), 361–384 (2004).
  Medline CASGoogle Scholar
• 120. Hesse C, Rosengren L, Vanmechelen E et al. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J. Alzheimers. Dis. 2(3–4), 199–206 (2000).
  Medline CASGoogle Scholar
• 121. Hesse C, Rosengren L, Andreasen N et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci. Lett. 297(3), 187–190 (2001).
  Medline CASGoogle Scholar
• 122. Hjalmarsson C, Bjerke M, Andersson B et al. Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke. J. Cent. Nerv. Syst. Dis. 6, 51–58 (2014).
  MedlineGoogle Scholar
• 123. Wunderlich MT, Lins H, Skalej M, Wallesch C-W, Goertler M. Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke. Clin. Neurol. Neurosurg. 108(6), 558–563 (2006).
  MedlineGoogle Scholar
• 124. Bielewicz J, Kurzepa J, Czekajska-Chehab E, Stelmasiak Z, Bartosik-Psujek H. Does serum Tau protein predict the outcome of patients with ischemic stroke? J. Mol. Neurosci. 43(3), 241–245 (2011).
  Medline CASGoogle Scholar
• 125. Hu H-T, Xiao F, Yan Y-Q, Wen S-Q, Zhang L. The prognostic value of serum tau in patients with intracerebral hemorrhage. Clin. Biochem. 45(16–17), 1320–1324 (2012).
  Medline CASGoogle Scholar
• 126. Braunewell KH, Gundelfinger ED. Intracellular neuronal calcium sensor proteins: a family of EF-hand calcium-binding proteins in search of a function. Cell Tissue Res. 295(1), 1–12 (1999).
  Medline CASGoogle Scholar
• 127. Dai FF, Zhang Y, Kang Y et al. The neuronal Ca2+ sensor protein visinin-like protein-1 is expressed in pancreatic islets and regulates insulin secretion. J. Biol. Chem. 281(31), 21942–21953 (2006).
  Medline CASGoogle Scholar
• 128. Wang L, Zeng D, Wang Q, Liu L, Lu T, Gao Y. Screening and identification of novel potential biomarkers for breast cancer brain metastases. Front. Oncol. 11, 784096 (2021).
  MedlineGoogle Scholar
• 129. Xie Q, Zhang X, Peng S et al. Identification of novel biomarkers in ischemic stroke: a genome-wide integrated analysis. BMC Med. Genet. 21(1), 66 (2020).
  Medline CASGoogle Scholar
• 130. Salussolia CL, Prodromou ML, Borker P, Wollmuth LP. Arrangement of subunits in functional NMDA receptors. J. Neurosci. 31(31), 11295–11304 (2011).
  Medline CASGoogle Scholar
• 131. Sharp CD, Fowler M, Jackson TH IV et al. Human neuroepithelial cells express NMDA receptors. BMC Neurosci. 4(1), (2003).
  MedlineGoogle Scholar
• 132. Káradóttir R, Cavelier P, Bergersen LH, Attwell D. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 438(7071), 1162–1166 (2005).
  Medline CASGoogle Scholar
• 133. Del Valle-Pinero AY, Suckow SK, Zhou Q, Perez FM, Verne GN, Caudle RM. Expression of the N-methyl-D-aspartate receptor NR1 splice variants and NR2 subunit subtypes in the rat colon. Neuroscience 147(1), 164–173 (2007).
  MedlineGoogle Scholar
• 134. Gascón S, Deogracias R, Sobrado M et al. Transcription of the NR1 subunit of the N-methyl-D-aspartate receptor is down-regulated by excitotoxic stimulation and cerebral ischemia. J. Biol. Chem. 280(41), 35018–35027 (2005).
  Medline CASGoogle Scholar
• 135. Gascón S, Sobrado M, Roda JM, Rodríguez-Peña A, Díaz-Guerra M. Excitotoxicity and focal cerebral ischemia induce truncation of the NR2A and NR2B subunits of the NMDA receptor and cleavage of the scaffolding protein PSD-95. Mol. Psychiatry. 13(1), 99–114 (2008).
  Medline CASGoogle Scholar
• 136. Dambinova SA, Khounteev GA, Izykenova GA, Zavolokov IG, Ilyukhina AY, Skoromets AA. Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin. Chem. 49(10), 1752–1762 (2003).
  Medline CASGoogle Scholar
• 137. Weissman JD, Khunteev GA, Heath R, Dambinova SA. NR2 antibodies: risk assessment of transient ischemic attack (TIA)/stroke in patients with history of isolated and multiple cerebrovascular events. J. Neurol. Sci. 300(1–2), 97–102 (2011).
  Medline CASGoogle Scholar
• 138. Dambinova SA, Bettermann K, Glynn T et al. Diagnostic potential of the NMDA receptor peptide assay for acute ischemic stroke. PLoS One. 7(7), e42362 (2012).
  Medline CASGoogle Scholar
• 139. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association: Application to clinical and public health practice: A statement for healthcare professionals from the centers for disease control and prevention and the American heart association. Circulation 107(3), 499–511 (2003).
  MedlineGoogle Scholar
• 140. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101(15), 1767–1772 (2000).
  Medline CASGoogle Scholar
• 141. Revilla M, Obach V, Cervera A, Dávalos A, Castillo J, Chamorro A. A -174G/C polymorphism of the interleukin-6 gene in patients with lacunar infarction. Neurosci. Lett. 324(1), 29–32 (2002).
  Medline CASGoogle Scholar
• 142. Kinlay S, Schwartz GG, Olsson AG et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 110(4), 386–391 (2004).
  Medline CASGoogle Scholar
• 143. Heeschen C, Dimmeler S, Hamm CW. Soluble CD40 ligand in acute coronary syndromes. ACC Curr. J. Rev. 12(3), 12–13 (2003).
  Google Scholar
• 144. Di Napoli M, Schwaninger M, Cappelli R et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members: a statement for health care professionals from the CRP pooling project members. Stroke 36(6), 1316–1329 (2005).
  MedlineGoogle Scholar
• 145. Ford ES, Giles WH. Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey: Findings from the Third National Health and Nutrition Examination Survey. Arterioscler. Thromb. Vasc. Biol. 20(4), 1052–1056 (2000).
  Medline CASGoogle Scholar
• 146. Gussekloo J, Schaap MC, Frölich M, Blauw GJ, Westendorp RG. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler. Thromb. Vasc. Biol. 20(4), 1047–1051 (2000).
  Medline CASGoogle Scholar
• 147. Elkind MSV, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch. Intern. Med. 166(19), 2073–2080 (2006).
  Medline CASGoogle Scholar
• 148. Weemering ML. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. AORN J. 73(6), 1176 (2001).
  Google Scholar
• 149. Morrow DA, Rifai N, Antman EM et al. Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy. J. Am. Coll. Cardiol. 35(2), 358–362 (2000).
  Medline CASGoogle Scholar